Core Viewpoint - The company, ZhiYuanKang Pharmaceutical-B (02410), announced that its investigational drug, TY-9591 (Axitinib), is proposed to be included in the priority review list by the National Medical Products Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [1] Group 1 - The proposed indication for TY-9591 is for adult patients with NSCLC who have either exon 19 deletions (19DEL) or exon 21 (L858R) substitution mutations, along with central nervous system (CNS) metastases [1] - The company's board has noted unusual fluctuations in the stock price and trading volume, but confirmed that they are not aware of any reasons for these fluctuations beyond what has been disclosed [1] - As of the date of the announcement, the board confirmed that the company's business operations are stable and progressing smoothly, with no significant matters requiring disclosure [1]
同源康医药-B(02410)：甲磺酸艾多替尼片(TY-9591片)拟纳入优先审评